Genome-wide Association Study and Meta-analysis on Alcohol-Associated Liver Cirrhosis Identifies Genetic Risk Factors.
paper
Cited
Public
Unavailable
- Authors
- Schwantes-An, Tae-Hwi; Darlay, Rebecca; Mathurin, Philippe; Masson, Steven; Liangpunsakul, Suthat; Mueller, Sebastian; Aithal, Guruprasad P; Eyer, Florian; Gleeson, Dermot; Thompson, Andrew; Muellhaupt, Beat; Stickel, Felix; Soyka, Michael; Goldman, David; Liang, Tiebing; Lumeng, Lawrence; Pirmohamed, Munir; Nalpas, Bertrand; Jacquet, Jean-Marc; Moirand, Romain; Nahon, Pierre; Naveau, Sylvie; Perney, Pascal; Botwin, Greg; Haber, Paul S; Seitz, Helmut K; Day, Christopher P; Foroud, Tatiana M; Daly, Ann K; Cordell, Heather J; Whitfield, John B; Morgan, Timothy R; Seth, Devanshi; GenomALC Consortium
- Year
- 2021
- Journal
- Hepatology (Baltimore, Md.)
- PMID
- 32853455
- DOI
- 10.1002/hep.31535
BACKGROUND AND AIMS: Only a minority of heavy drinkers progress to alcohol-associated cirrhosis (ALC). The aim of this study was to identify common genetic variants that underlie risk for ALC. APPROACH AND RESULTS: We analyzed data from 1,128 subjects of European ancestry with ALC and 614 heavy-drinking subjects without known liver disease from Australia, the United States, the United Kingdom, and three countries in Europe. A genome-wide association study (GWAS) was performed, adjusting for principal components and clinical covariates (alcohol use, age, sex, body mass index, and diabetes). We validated our GWAS findings using UK Biobank. We then performed a meta-analysis combining data from our study, the UK Biobank, and a previously published GWAS. Our GWAS found genome-wide significant risk association of rs738409 in patatin-like phospholipase domain containing 3 (PNPLA3) (odds ratio [OR]Β =Β 2.19 [G allele], PΒ =Β 4.93Β ΓΒ 10 ) and rs4607179 near HSD17B13 (ORΒ =Β 0.57 [C allele], PΒ =Β 1.09Β ΓΒ 10 ) with ALC. Conditional analysis accounting for the PNPLA3 and HSD17B13 loci identified a protective association at rs374702773 in Fas-associated factor family member 2 (FAF2) (ORΒ =Β 0.61 [del(T) allele], PΒ =Β 2.56Β ΓΒ 10 ) for ALC. This association was replicated in the UK Biobank using conditional analysis (ORΒ =Β 0.79, PΒ =Β 0.001). Meta-analysis (without conditioning) confirmed genome-wide significance for the identified FAF2 locus as well as PNPLA3 and HSD17B13. Two other previously known loci (SERPINA1 and SUGP1/TM6SF2) were also genome-wide significant in the meta-analysis. GeneOntology pathway analysis identified lipid droplets as the target for several identified genes. In conclusion, our GWAS identified a locus at FAF2 associated with reduced risk of ALC among heavy drinkers. Like the PNPLA3 and HSD17B13 gene products, the FAF2 product has been localized to fat droplets in hepatocytes. CONCLUSIONS: Our genetic findings implicate lipid droplets in the biological pathway(s) underlying ALC.
No figures extracted from this document.
No chunks β full text not yet ingested.
No entities extracted from this document yet.
No uploaded files.
Not in any collection.
No citations found.
In this knowledge base
| Title | Year | PMID |
|---|---|---|
| Gene-based polygenic risk scores analysis of alcohol use disorder in African Americans. | 2022 | 35790736 |
External
| Title | Authors | Journal | Year | Link |
|---|---|---|---|---|
| Evaluation of Pathogenic Variants Associated With Monogenic Disorders of Dyslipidemia in Patients With Well Characterised MASLD. | Schwantes-An TH et al. | β | 2026 | β |
| Genetic evidence that FGF21 signaling reduces problematic alcohol use and alcohol-related liver disease. | Rosoff DB et al. | β | 2026 | β |
| Genetic Variants in Liver Cirrhosis: Classifications, Mechanisms, and Implications for Clinical Practice. | Raghavan RP et al. | β | 2026 | β |
| Racial Disparities in Clinical and Cardiometabolic Outcomes Among Patients with Alcohol-Associated Liver Disease. | Hariharan P et al. | β | 2026 | β |
| The versatile interplay between steatotic liver disease and liver cancer. | Rahbari M et al. | β | 2026 | β |
| A comprehensive evaluation of candidate genetic polymorphisms in a large histologically characterized MASLD cohort using a novel framework. | Hakim A et al. | β | 2025 | β |
| Advanced alcoholic liver disease driven by a proferroptotic diet. | Liang Y et al. | β | 2025 | β |
| Cohort Profile: Taizhou Study of Liver Diseases (T-SOLID). | Liu Z et al. | β | 2025 | β |
| Exome-wide association analysis identifies novel risk loci for alcohol-associated hepatitis. | Yuan Q et al. | β | 2025 | β |
| Genetic insights into alcohol-associated liver disease: integrative transcriptome-wide analysis identifies novel susceptibility genes. | Wang Q et al. | β | 2025 | β |
| Genomic approaches to explore susceptibility and pathogenesis of alcohol use disorder and alcohol-associated liver disease. | Norden-Krichmar TM et al. | β | 2025 | β |
| Human genetics of metabolic dysfunction-associated steatotic liver disease: from variants to cause to precision treatment. | Chen VL et al. | β | 2025 | β |
| Letter: Addressing the Growing Disparities in Alcohol-Associated Liver Disease-A Call for Equitable Healthcare Strategies: Authors' Reply. | Rady ED et al. | β | 2025 | β |
| Metabolic dysfunction and alcohol-related liver disease (MetALD): Position statement by an expert panel on alcohol-related liver disease. | Arab JP et al. | β | 2025 | β |
| Mutations in the bone morphogenetic protein signaling pathway sensitize zebrafish and humans to ethanol-induced jaw malformations. | Klem JR et al. | β | 2025 | β |
| Parental liver disease mortality is associated with unfavorable outcomes in patients with alcohol-associated hepatitis. | Tu W et al. | β | 2025 | β |
| PNPLA3 in Alcohol-Related Liver Disease. | Galvanin C et al. | β | 2025 | β |
| Prevalence and Clinical Correlation of Cardiometabolic Risk Factors in Alcohol-Related Liver Disease and Metabolic Dysfunction and Alcohol Associated Liver Disease (MetALD). | Dixon W et al. | β | 2025 | β |
| Recent advances in MASLD genetics: Insights into disease mechanisms and the next frontiers in clinical application. | Chen VL et al. | β | 2025 | β |
| Silencing FAF2 mitigates alcohol-induced hepatic steatosis by modulating lipolysis and PCSK9 pathway. | Huda N et al. | β | 2025 | β |
| Steatotic liver disease and cancer: from pathogenesis to therapeutic targets. | Yang Z et al. | β | 2025 | β |
| A Comprehensive Investigation of Dietary Micronutrient Intakes and Risk of Alcoholic Liver Disease. | Li J et al. | β | 2024 | β |
| Alcohol and Hepatocellular Carcinoma. | Ha NB et al. | β | 2024 | β |
| Alcohol-associated liver disease. | Mackowiak B et al. | β | 2024 | β |
| Alcohol-associated liver disease-Global epidemiology. | Γ berg F et al. | β | 2024 | β |
| A patient-based iPSC-derived hepatocyte model of alcohol-associated cirrhosis reveals bioenergetic insights into disease pathogenesis. | Mukhopadhyay B et al. | β | 2024 | β |
| A polygenic risk score for alcohol-associated cirrhosis among heavy drinkers with European ancestry. | Schwantes-An TH et al. | β | 2024 | β |
| Cell-to-cell and organ-to-organ crosstalk in the pathogenesis of alcohol-associated liver disease. | Gao H et al. | β | 2024 | β |
| Clinical features of individuals with laboratory values suggestive of advanced liver fibrosis when first treated for alcohol use disorder. | Zuluaga P et al. | β | 2024 | β |
| Effect of donor <i>HSD17B13</i> genotype on patient survival after liver transplant: a retrospective cohort study. | Kozlitina J et al. | β | 2024 | β |
| FK-binding protein 5: Possible relevance to the pathogenesis of metabolic dysfunction and alcohol-associated liver disease. | Ma J et al. | β | 2024 | β |
| MetALD: Does it require a different therapeutic option? | Marek GW et al. | β | 2024 | β |
| Mimicking chronic alcohol effects through a controlled and sustained ethanol release device. | Kim W et al. | β | 2024 | β |
| NRDE2 deficiency impairs homologous recombination repair and sensitizes hepatocellular carcinoma to PARP inhibitors. | Wang Y et al. | β | 2024 | β |
| PNPLA3 I148Β M genetic variant in autoimmune hepatitis characterises advanced disease at diagnosis and reduced survival free of cirrhotic events and liver-related mortality. | Azariadis K et al. | β | 2024 | β |
| Polymorphisms in the choline transporter SLC44A1 are associated with reduced cognitive performance in normotypic but not prenatal alcohol-exposed children. | Smith SM et al. | β | 2024 | β |
| Protein truncating variants in mitochondrial-related nuclear genes and the risk of chronic liver disease. | Yuan H et al. | β | 2024 | β |
| Advances in the understanding and management of alcohol-related liver disease. | Thursz M et al. | β | 2023 | β |
| Alcohol-Associated Liver Disease: Evolving Concepts and Treatments. | Prince DS et al. | β | 2023 | β |
| Association of HSD17B13 and PNPLA3 With Liver Enzymes and Fibrosis in Hispanic/Latino Individuals of Diverse Genetic Ancestries. | Rutledge SM et al. | β | 2023 | β |
| Emerging Biomarkers in Alcohol-associated Hepatitis. | Im GY | β | 2023 | β |
| Global epidemiology of alcohol-associated cirrhosis and HCC: trends, projections and risk factors. | Huang DQ et al. | β | 2023 | β |
| Identification of 13 Novel Loci in a Genome-Wide Association Study on Taiwanese with Hepatocellular Carcinoma. | Liu TY et al. | β | 2023 | β |
| Immunology of human fibrosis. | Bhattacharya M et al. | β | 2023 | β |
| Investigating the role of lipid genes in liver disease using fatty liver models of alcohol and high fat in zebrafish (Danio rerio). | Shihana F et al. | β | 2023 | β |
| Metabolic Hijacking of Hexose Metabolism to Ascorbate Synthesis Is the Unifying Biochemical Basis of Murine Liver Fibrosis. | BeyoΔlu D et al. | β | 2023 | β |
| MicroRNAs Signature Panel Identifies Heavy Drinkers with Alcohol-Associated Cirrhosis from Heavy Drinkers without Liver Injury. | Shihana F et al. | β | 2023 | β |
| Mutations in the Bone Morphogenetic Protein signaling pathway sensitize zebrafish and humans to ethanol-induced jaw malformations | Klem JR et al. | β | 2023 | β |
| New Diagnostic and Prognostic Models for the Development of Alcoholic Cirrhosis Based on Genetic Predisposition and Alcohol History. | Mischitelli M et al. | β | 2023 | β |
| The Model for End-stage Liver Disease 3.0 is not superior to the Model for End-stage Liver Disease-Na in predicting survival: A retrospective cohort study. | Duan F et al. | β | 2023 | β |
| Unraveling the roles of excessive alcohol use and liver disease in mortality. | Mitchell MC et al. | β | 2023 | β |
| A genetic risk score and diabetes predict development of alcohol-related cirrhosis in drinkers. | Whitfield JB et al. | β | 2022 | β |
| All-cause and liver-related mortality risk factors in excessive drinkers: Analysis of data from the UK biobank. | Whitfield JB et al. | β | 2022 | β |
| [French clinical practice guidelines for the diagnosis and management of lung disease with alpha 1-antitrypsin deficiency]. | Mornex JF et al. | β | 2022 | β |
| Gene-based polygenic risk scores analysis of alcohol use disorder in African Americans. | Lai D et al. | β | 2022 | β |
| Impact of non-invasive biomarkers on hepatology practice: Past, present and future. | Anstee QM et al. | β | 2022 | β |
| Liver specific, systemic and genetic contributors to alcohol-related liver disease progression. | Schnabl B et al. | β | 2022 | β |
| Natural History of Alcohol-Associated Liver Disease: Understanding the Changing Landscape of Pathophysiology and Patient Care. | Bajaj JS et al. | β | 2022 | β |
| Pathogenesis of Alcohol-Associated Liver Disease. | Osna NA et al. | β | 2022 | β |
| Pharmacogenetics of the cytochromes P450: Selected pharmacological and toxicological aspects. | Daly AK | β | 2022 | β |
| Therapeutic RNA-silencing oligonucleotides in metabolic diseases. | Goga A et al. | β | 2022 | β |
| Transcriptomic Analysis Reveals the Messenger RNAs Responsible for the Progression of Alcoholic Cirrhosis. | Yang Z et al. | β | 2022 | β |
| A genome-first approach to mortality and metabolic phenotypes in <i>MTARC1</i> p.Ala165Thr (rs2642438) heterozygotes and homozygotes. | Schneider CV et al. | β | 2021 | β |
| A transcriptome-wide association study to detect novel genes for volumetric bone mineral density. | Liu A et al. | β | 2021 | β |
| Biochemical Mechanisms Associating Alcohol Use Disorders with Cancers. | Rodriguez FD et al. | β | 2021 | β |
| Epidemiology of Alcohol-Associated Liver Disease. | Han S et al. | β | 2021 | β |
| Genetic and environmental influences on the progression from alcohol use disorder to alcohol-related medical conditions. | Edwards AC et al. | β | 2021 | β |
| Genetic and Environmental Susceptibility to Alcoholic Hepatitis. | Morgan MY et al. | β | 2021 | β |
| <i>NOTCH3</i> rs1043996 Polymorphism Is Associated with the Occurrence of Alcoholic Liver Cirrhosis Independently of <i>PNPLA3</i> and <i>TM6SF2</i> Polymorphisms. | Bainrauch A et al. | β | 2021 | β |
| Leveraging Single-Cell RNA-seq Data to Uncover the Association Between Cell Type and Chronic Liver Diseases. | Ye X et al. | β | 2021 | β |
| Lipid Droplet-Associated Factors, PNPLA3, TM6SF2, and HSD17B Proteins in Hepatopancreatobiliary Cancer. | Sunami Y et al. | β | 2021 | β |
| Role of candidate gene variants in modulating the risk and severity of alcoholic hepatitis. | Beaudoin JJ et al. | β | 2021 | β |
| Stress-Responsive Gene FK506-Binding Protein 51 Mediates Alcohol-Induced Liver Injury Through the Hippo Pathway and Chemokine (C-X-C Motif) Ligand 1 Signaling. | Kusumanchi P et al. | β | 2021 | β |
| The History of Alcoholic Liver Disease: From an Unrecognized Disease to One of the Most Frequent Diseases in Hepatology. | Seitz HK et al. | β | 2021 | β |
| Bergenin Attenuates Hepatic Fibrosis by Regulating Autophagy Mediated by the PPAR-<i>Ξ³</i>/TGF-<i>Ξ²</i> Pathway. | Xia Y et al. | β | 2020 | β |